Blasts 5 Percent or More of Peripheral Blood White Cells
1 clinical trials · Condition
◉ Watch Blasts 5 Percent or More of Peripheral Blood White Cells
| Record | Firm | Date |
|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (NCT03851081) | Roswell Park Cancer Institute | 2021-01-21 |
Track Blasts 5 Percent or More of Peripheral Blood White Cells automatically
Every clearance here is in the API, with alerts when new ones post.